Cannabinoid-based medications show promise for treating addiction to other substances
After rimonabant was pulled for psychiatric side effects, newer cannabinoid strategies including neutral CB1 antagonists, CB2 agonists, and phytocannabinoids like CBD show therapeutic potential for substance use disorders in animal and early human studies.
Quick Facts
What This Study Found
Neutral CB1R antagonists (AM4113), CB2R agonists (JWH133, Xie2-64), and phytocannabinoids (CBD, beta-caryophyllene, THCV) show therapeutic potential for SUDs in animals. Clinical trials of dronabinol, nabilone, and the FAAH inhibitor PF-04457845 show promising results for cannabis and opioid withdrawal.
Key Numbers
Rimonabant withdrawn from clinical trials worldwide in 2008 due to depression and suicidality. Multiple new strategies now under investigation: peripheral CB1R antagonists, neutral CB1R antagonists, allosteric CB1R modulators, CB2R agonists, FAAH inhibitors, MAGL inhibitors, FABP inhibitors.
How They Did This
Comprehensive review of endocannabinoid system biology, cannabis reward and aversion mechanisms, and cannabinoid-based medication development for substance use disorders, covering preclinical and clinical trial data.
Why This Research Matters
Substance use disorders affect millions with limited treatment options. The endocannabinoid system is deeply involved in reward pathways, making cannabinoid-based drugs logical therapeutic candidates. The field has recovered from the rimonabant setback with more targeted strategies.
The Bigger Picture
The rimonabant failure taught researchers that bluntly blocking CB1 receptors throughout the brain is dangerous. The next generation of cannabinoid therapies is more nuanced, targeting specific receptor subtypes, peripheral locations, or endocannabinoid metabolism rather than the CB1 receptor directly.
What This Study Doesn't Tell Us
Most evidence from animal models. Clinical trial data limited to a few compounds. Long-term safety of newer approaches unknown. Translation from animal addiction models to human substance use disorders is historically unreliable.
Questions This Raises
- ?Will peripheral CB1 antagonists avoid the psychiatric risks of rimonabant?
- ?Can CBD effectively treat opioid or stimulant addiction in controlled trials?
- ?Which specific cannabinoid strategy is most promising for each type of substance use disorder?
Trust & Context
- Key Stat:
- After rimonabant failure, 7+ new cannabinoid-based addiction treatment strategies are now under study
- Evidence Grade:
- Moderate: comprehensive review covering both preclinical and early clinical data, though most evidence is still from animal models.
- Study Age:
- Published in 2019.
- Original Title:
- Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders.
- Published In:
- CNS drugs, 33(10), 1001-1030 (2019)
- Authors:
- Galaj, Ewa(6), Xi, Zheng-Xiong(9)
- Database ID:
- RTHC-02042
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Can cannabinoids help treat addiction?
Animal studies show several cannabinoid-based approaches reduce drug-seeking behavior. Early clinical trials of dronabinol, nabilone, and FAAH inhibitors show promise for cannabis and opioid withdrawal. However, large-scale human trials are still needed.
What happened with rimonabant?
Rimonabant was a promising CB1 receptor blocker that reduced substance use and obesity in trials, but caused depression and suicidal thoughts. It was pulled worldwide in 2008, redirecting research toward safer cannabinoid-based strategies.
Read More on RethinkTHC
- cannabis-dependence-physical-psychological-addiction-science
- cannabis-perception-vs-evidence-gap
- cannabis-use-disorder-test
- cross-addiction-quit-weed-start-drinking
- is-weed-addictive
- is-weed-addictive-science
- quitting-weed-and-alcohol
- rehab-for-weed-addiction-necessary
- signs-of-cannabis-use-disorder
- weed-vape-pen-addiction
Cite This Study
https://rethinkthc.com/research/RTHC-02042APA
Galaj, Ewa; Xi, Zheng-Xiong. (2019). Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders.. CNS drugs, 33(10), 1001-1030. https://doi.org/10.1007/s40263-019-00664-w
MLA
Galaj, Ewa, et al. "Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders.." CNS drugs, 2019. https://doi.org/10.1007/s40263-019-00664-w
RethinkTHC
RethinkTHC Research Database. "Potential of Cannabinoid Receptor Ligands as Treatment for S..." RTHC-02042. Retrieved from https://rethinkthc.com/research/galaj-2019-potential-of-cannabinoid-receptor
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.